Corresponding symptoms
Age-related macular degeneration (AMD): The RPE cells experience senescent functional decline or loss, which in turn causes the atrophy or apoptosis of the photoreceptor cells in the retina, ultimately leading to the loss of visual function. The global incidence rate of AMD is approximately 3%, and there are about 72 million patients in China. Dry AMD: It accounts for 85%-90% of the total number of AMD patients. The late-stage clinical manifestation is geographic atrophy (GA) of the retina and choroid in the posterior pole of the eye.
Therapeutic principle
RPE cells: They are a single layer of cells between the neural retina and the choroidal blood vessels. The cells maintain their shape through tight junctions and have functions such as barrier function, phagocytic function, neuroprotection, and nutrition. Starting from the pathogenic mechanism of macular degeneration (atrophy and apoptosis of RPE cells), it can effectively restore the visual function of patients. The effect of a single treatment is long-lasting (> 3 years), and the cell dosage is small (in the order of magnitude of 10 to the power of 5), which is the hope for curing macular degeneration diseases.
Pipeline progress
